Source: https://www.federalregister.gov/documents/2006/03/31/06-3122/new-animal-drugs-for-use-in-animal-feeds-bacitracin-nitarsone-zoalene
Timestamp: 2018-07-23 18:39:32
Document Index: 223929007

Matched Legal Cases: ['§\u2009558', '§\u2009558', '§\u2009558', '§\u2009558', '§\u2009558', '§\u2009558', '§\u2009558', '§\u2009510', '§\u2009558', '§\u2009510']

Federal Register :: New Animal Drugs for Use in Animal Feeds; Bacitracin; Nitarsone; Zoalene
New Animal Drugs for Use in Animal Feeds; Bacitracin; Nitarsone; Zoalene
https://www.federalregister.gov/d/06-3122 https://www.federalregister.gov/d/06-3122
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of three supplemental new animal drug applications (NADAs) filed by Alpharma, Inc. Two of the supplemental NADAs provide for the use of approved, single-ingredient Type A medicated articles containing bacitracin methylene disalicylate and zoalene, with or without roxarsone, to formulate two-way or three-way combination drug Type C medicated feeds for replacement chickens. The third NADA provides for the use of bacitracin zinc and nitarsone single-ingredient Type A medicated articles for two-way combination Type C medicated feeds for growing turkeys. These approvals reflect FDA's effectiveness conclusions, which relied on the National Academy of Sciences/National Research Council (NAS/NRC) Drug Efficacy Study Group's evaluation of the effectiveness of these drugs when used in animal feed as single ingredients.
In the Federal Register of August 8, 2003 (68 FR 47332), as corrected October 7, 2003 (68 FR 57911), as part of the Drug Efficacy Study Implementation (DESI) program CVM announced the effective conditions of use for several drug products and use combinations listed in 21 CFR 558.15. CVM proposed to withdraw the NADAs for those products or use combinations lacking substantial evidence of effectiveness following a 90-day opportunity to supplement the NADAs with labeling conforming to the relevant findings of effectiveness. Alpharma, Inc., One Executive Dr., Fort Lee, NJ 07024, filed supplements to three of its approved NADAs to revise the labeling of its products to comply with these findings of effectiveness.
Alpharma, Inc., filed a supplement to approved NADA 141-130 for use of bacitracin methylene disalicylate and zoalene Type A medicated articles to formulate two-way combination drug Type C medicated feeds. This supplemental NADA provides for the use of combination feeds containing BMD (bacitracin methylene disalicylate) at 4 to 50 grams per ton (g/ton) and ZOAMIX (zoalene) at 36.3 to 113.5 g/ton of feed in replacement chickens for increased rate of weight gain and improved feed efficiency; and for development of active immunity to coccidiosis.
Alpharma, Inc., also filed a supplement to approved NADA 141-131 for use of bacitracin methylene disalicylate, zoalene, and roxarsone single-ingredient Type A medicated articles to make three-way combination drug Type C medicated feeds. This supplemental NADA provides for the use of combination feeds containing BMD (bacitracin methylene disalicylate) at 4 to 50 g/ton, ZOAMIX (zoalene) at 36.3 to 113.5 g/ton, and 3-NITRO (roxarsone) at 22.7 to 45.4 g/ton of feed in replacement chickens for increased rate of weight gain and improved feed efficiency; for development of active immunity to coccidiosis; and for improved pigmentation.
Alpharma, Inc., also filed a supplement to approved NADA 141-132 for use of bacitracin zinc and nitarsone single-ingredient Type A medicated articles to make two-way combination drug Type C medicated feeds. This supplemental NADA provides for the use of combination feeds containing ALBAC (bacitracin zinc) at 4 to 50 g/ton and HISTOSTAT (nitarsone) at 170 g/ton (0.01875 percent) of feed in growing turkeys for increased rate of weight gain and improved feed efficiency; and as an aid in the prevention of blackhead.
Products that comply with FDA's findings of effectiveness are eligible for copying as described in the Generic Animal Drug and Patent Term Restoration Act Policy Letter Eight, August 21, 1991 (56 FR 41561). Accordingly, sponsors may now obtain approval of abbreviated NADAs for Start Printed Page 16223these three combination drug medicated feeds.
The NADAs are approved as of February 15, 2006, and the regulations are amended in 21 CFR 558.76, 558.78, 558.369, and 558.680 to reflect the approval. Approval of these supplemental NADAs did not require review of any new safety or effectiveness data. Therefore, a freedom of information summary was not prepared.
2. In § 558.76, amend paragraph (d)(3)(xviii) by adding “or roxarsone” after “arsanilic acid”.
3. In § 558.78, amend paragraph (d)(3) by redesignating paragraphs (d)(3)(x) through (d)(3)(xii) as paragraphs (d)(3)(xi) through (d)(3)(xiii); and add new paragraph (d)(3)(x) to read as follows:
(x) Nitarsone as in § 558.369.
§ 558.369
4. In § 558.369, amend paragraph (d)(2)(i) by adding “or bacitracin zinc” after “disalicylate”.
5. In § 558.680, amend the table in paragraph (d)(1)(i), after the entry for “Arsanilic acid 90 (0.01%) plus penicillin 2.4 to 50” by adding entries for “Bacitracin 4 to 50” and “Bacitracin methylene disalicylate 4 to 50 plus roxarsone 22.7 to 45.4” to read as follows:
Bacitracin 4 to 50 Replacement chickens: For development of active immunity to coccidiosis; for increased rate of weight gain, improved feed efficiency Feed as in subtable in § 558.680(d)(1)(i); grower ration not to be fed to birds over 14 weeks of age. As bacitracin methylene disalicylate provided by No. 046573 in § 510.600(c) of this chapter
Bacitracin methylene disalicylate 4 to 50 plus roxarsone 22.7 to 45.4 Replacement chickens: For development of active immunity to coccidiosis; for increased rate of weight gain, improved feed efficiency, and improved pigmentation Feed as in subtable in § 558.680(d)(1)(i); grower ration not to be fed to birds over 14 weeks of age. Discontinue use 5 days before slaughter; as sole source of organic arsenic; drug overdose or lack of water may result in leg weakness. As bacitracin methylene disalicylate and roxarsone provided by No. 046573 in § 510.600(c) of this chapter
[FR Doc. 06-3122 Filed 3-30-06; 8:45 am]